Navigation Links
Empi's Hybresis Solves 'Pain Points' for Physical Therapists
Date:1/21/2008

PTs Report Wireless Hybrid Iontophoresis System Delivers Precise Dose Control, Reduces Patient Discomfort and Shortens In-Clinic Treatment Times

ST. PAUL, Minn., Jan. 21 /PRNewswire/ -- For years, physical therapists have relied on iontophoresis as a safe, reliable and effective drug delivery method. At the same time, most PTs have suffered the drawbacks of traditional dose controllers, lead wires and patch-only iontophoresis systems. This traditional system also includes extensive wear times, patient patch sensitivity and imprecise dosage delivery, which can all lead to unpredictable results. The industry's first wireless hybrid iontophoresis system, Hybresis, is a convenient, needle-free drug delivery system that allows clinicians to treat more patients while improving overall care by reducing patient discomfort and inconvenience.

According to the National Institute of Health (NIH), more than 50 million Americans annually suffer from chronic pain. Traditional pain management treatments include needle injections of anti-inflammatory drugs, narcotics, time-consuming in-clinic treatments or surgery -- all of which often result in unnecessary pain, side effects, anxiety or inconvenience for patients. Hybresis significantly reduces the total in-clinic time, enabling PTs to help move more patients through the clinic faster. Ultimately, PTs can spend more time on providing care.

PTs, including Rick Mewes, OCS, who works in a sports medicine clinic in Minneapolis, have reported that the Hybresis system offers the power of the traditional dose controllers and lead wires, with the flexibility of a patch. "With Hybresis, my patients can be treated effectively in less than half the time it takes for traditional iontophoresis," said Mewes. "My patients have also responded favorably -- opting for the convenience that Hybresis offers over other methods. The greatest benefit I've seen from using Hybresis is that I can now spend more time providing therapy, rather than wasting the time that's required for other iontophoresis treatments to be administered."

The Hybresis system consists of a charging station with four controller bays, a wireless, rechargeable controller and an iontophoresis patch. The patches have an internal battery, which powers the delivery of the medicine during and upon removal of the external Hybresis device. The Hybresis Dose Controller connects to the patch and powers a three-minute initial treatment, allowing for increased absorption that leads to more controlled therapy. After three minutes, the Dose Controller is removed and the Patch is powered to deliver the remainder of the therapy to the patient -- providing patients with the mobility to leave the clinic. After approximately one to two hours, the treatment is complete and patients should remove and discard the patch.

Hybresis patient benefits include:

-- Significantly shorter in-clinic and overall wear times

-- A more discreet and comfortable system which reduces the likelihood of

skin irritation

-- A gentle, hypoallergenic patch adhesive and ergonomic design that

conforms to the treatment area

-- Virtually painless treatment without anti-inflammatory injections,

thereby reducing the risk of infection and minimizing potential for

tissue trauma from the needle

"My pain used to prevent me from doing everyday activities like lifting weights, exercising and using some hand tools on do-it-yourself projects," said patient Bob Gubrud, who recently suffered a shoulder injury due to a bike accident. "Since my PT offered Hybresis, the road to recovery has been much faster. I was in and out of the clinic quickly and able to get back to doing my everyday activities feeling pain-free."

"With a continued rise in the aging population and the number of people suffering from chronic pain, America today is facing a pain epidemic. Now more than ever, healthcare professionals need the right tools to treat their patients, who often have a number of concerns about pain management," said Don Dumoulin, President of Empi. "With Hybresis, Empi has taken another step in providing patients with more options for therapeutic relief. Essentially, we've taken the 'pain' out of drug delivery for both patients and the healthcare professionals."

Empi's Hybresis system has regulatory approval through the 510(k) market clearance process of the U.S. Food and Drug Administration (FDA). Prescription by a licensed physician is required.

For more information about Hybresis, please visit http://www.hybresis.com.

About Empi

Empi, a DJO company, is a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. Headquartered in St. Paul, Minnesota, Empi is committed to delivering positive patient outcomes and providing innovative products specifically designed to meet the needs of the patient, medical professional and payor. More information about Empi and its wide range of pain management products and services can be found on the Company's Web site, http://www.empi.com. More information about DJO can be found on the Company's Web Site at http://www.DJOglobal.com.

Media Contact:

Susan Lombardo

Lois Paul & Partners

781.782.5767

susan_lombardo@lpp.com


'/>"/>
SOURCE Empi
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. Whiplash may produce delayed jaw pain
3. Hypnosis Eases Pain of Breast Cancer Surgery
4. Whiplash May Result in Delayed Jaw Pain
5. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
6. Knee Pain May Signal Lung Cancer
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. New study examines brain-gut relationship in those suffering with stomach pain or discomfort
10. Pain patients at risk for sleep apnea
11. Painless Hemorrhoid Treatment Adds Management Punch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... ... services, is proud to announce the guest speaker lineup* for its second annual ... Alliance of Healthcare Purchaser Coalitions; Dr. Keith Fernandez of Privia Health; and Lisa ...
(Date:6/28/2017)... PA (PRWEB) , ... June 28, 2017 , ... ... host a one-day corporate governance program for mid-market executives as a kick-off to ... be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology: